Early use of alendronate as a protective factor against the development of glucocorticoid-induced bone loss in childhood-onset rheumatic diseases: a cross-sectional study

• Autores principales: Yuzaburo Inoue (Autor), Kanako Mitsunaga (Autor), Takeshi Yamamoto (Autor), Koki Chiba (Autor), Fumiya Yamaide (Autor), Taiji Nakano (Autor), Yoshinori Morita (Autor), Akiko Yamaide (Autor), Shuichi Suzuki (Autor), Takayasu Arima (Autor), Ken-ichi Yamaguchi (Autor), Minako Tomiita (Autor), Naoki Shimojo (Autor), Yoichi Kohno (Autor)
• Formato: Libro
• Publicado: BMC, 2018-06-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Abstract Background Bisphosphonates are recommended for use as first-line therapy for the prevention and treatment of glucocorticoid-induced osteoporosis in adults. However, the appropriate usage of bisphosphonates for the prevention or treatment of glucocorticoid-induced osteoporosis in children re...